SAB Biotherapeutics Appoints Dr. Jay Skyler to Board of Directors

SAB Biotherapeutics, Inc.

Dr. Jay Skyler appointed as Class I director, effective May 3, 2024, to serve until 2025 annual meeting.
Skyler is Professor of Medicine at University of Miami, former President of American Diabetes Association, and served on boards of DexCom, Amylin, and MiniMed.
His appointment brings deep Type 1 diabetes expertise to SAB's board, supporting SAB-142 immunotherapy program.
No material transaction or family relationship with any director or officer; compensation consistent with non-employee directors.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Jay S. Skyler

Class I director

SABS · SAB Biotherapeutics, Inc.

Effective: 2024-05-03
Filed: May 8, 2024, 7:59 PM ET

On May 3, 2024, the Nominating and Corporate Governance Committee (the “ Committee ”) of the Board of Directors (the “ Board ”) of SAB Biotherapeutics, Inc., a Delaware corporation (the “ Company ”), recommended the appointment of, and the Board subsequently appointed, Dr. Jay S. Skyler to serve as a Class I director of the Company, effective as of May 3, 2024, and to serve until the Company’s 2025 annual meeting of stockholders or until Dr. Skyler’s successor is duly elected and qualified.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Jay S. Skyler was appointed as Class I director at SAB Biotherapeutics, Inc..

Action: appointed
Role: Class I director

Exact text from the filing

On May 3, 2024, the Nominating and Corporate Governance Committee (the “ Committee ”) of the Board of Directors (the “ Board ”) of SAB Biotherapeutics, Inc., a Delaware corporation (the “ Company ”), recommended the appointment of, and the Board subsequently appointed, Dr. Jay S. Skyler to serve as a Class I director of the Company, effective as of May 3, 2024, and to serve until the Company’s 2025 annual meeting of stockholders or until Dr. Skyler’s successor is duly elected and qualified.

View on SEC.gov

SAB Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-054868

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.